Mayo Clinic and North Central Cancer Treatment Group hot flash studies: A 20-year experience

Charles Lawrence Loprinzi, Debra L. Barton, Jeff A Sloan, Paul J. Novotny, Shaker R. Dakhil, Joseph D. Verdirame, Wilma H. Knutson, Joseph Kelaghan, Brad Christensen

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective: This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group. Design: Prospective clinical trials performed by these investigators are illustrated, described, and discussed. Results: Ten randomized, controlled (eight placebo controlled), double-blind clinical trials were conducted involving a total of 1,581 women and three placebo-controlled, double-blind clinical trials involving a total of 329 men were conducted. In addition, 14 pilot trials, having involved more than 325 participants to date, were conducted. Conclusions: Data from the pilot trials have given direction for substances that ought to be further explored in more definitive studies. In men, randomized studies demonstrate that hot flashes are markedly decreased by low doses of megestrol acetate, moderately decreased by gabapentin, but not substantially decreased by clonidine. Results from the randomized trials in women demonstrate that hot flashes are markedly decreased by relatively low doses of progestational agents (megestrol acetate and medroxyprogesterone acetate), moderately decreased by venlafaxine, mildly to moderately decreased by fluoxetine, mildly decreased by clonidine, but not substantially decreased by vitamin E, a soy phytoestrogen product, or black cohosh. Last, the data investigated in these studies support the hypothesis that, for the treatment of hot flashes in women, the results of therapeutic maneuvers are similar regardless of whether the patient has a history of breast cancer and/or is taking tamoxifen.

Original languageEnglish (US)
Pages (from-to)655-660
Number of pages6
JournalMenopause
Volume15
Issue number4
DOIs
StatePublished - Jul 2008

Fingerprint

Hot Flashes
Megestrol Acetate
Clinical Trials
Clonidine
Neoplasms
Cimicifuga
Placebos
Phytoestrogens
Medroxyprogesterone Acetate
Fluoxetine
Progestins
Tamoxifen
Therapeutics
Vitamin E
Research Personnel
Breast Neoplasms

Keywords

  • Breast cancer
  • Hot flashes
  • Hot flushes

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Mayo Clinic and North Central Cancer Treatment Group hot flash studies : A 20-year experience. / Loprinzi, Charles Lawrence; Barton, Debra L.; Sloan, Jeff A; Novotny, Paul J.; Dakhil, Shaker R.; Verdirame, Joseph D.; Knutson, Wilma H.; Kelaghan, Joseph; Christensen, Brad.

In: Menopause, Vol. 15, No. 4, 07.2008, p. 655-660.

Research output: Contribution to journalArticle

Loprinzi, CL, Barton, DL, Sloan, JA, Novotny, PJ, Dakhil, SR, Verdirame, JD, Knutson, WH, Kelaghan, J & Christensen, B 2008, 'Mayo Clinic and North Central Cancer Treatment Group hot flash studies: A 20-year experience', Menopause, vol. 15, no. 4, pp. 655-660. https://doi.org/10.1097/gme.0b013e3181679150
Loprinzi, Charles Lawrence ; Barton, Debra L. ; Sloan, Jeff A ; Novotny, Paul J. ; Dakhil, Shaker R. ; Verdirame, Joseph D. ; Knutson, Wilma H. ; Kelaghan, Joseph ; Christensen, Brad. / Mayo Clinic and North Central Cancer Treatment Group hot flash studies : A 20-year experience. In: Menopause. 2008 ; Vol. 15, No. 4. pp. 655-660.
@article{f667a1724b694c66af85847961e0fedc,
title = "Mayo Clinic and North Central Cancer Treatment Group hot flash studies: A 20-year experience",
abstract = "Objective: This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group. Design: Prospective clinical trials performed by these investigators are illustrated, described, and discussed. Results: Ten randomized, controlled (eight placebo controlled), double-blind clinical trials were conducted involving a total of 1,581 women and three placebo-controlled, double-blind clinical trials involving a total of 329 men were conducted. In addition, 14 pilot trials, having involved more than 325 participants to date, were conducted. Conclusions: Data from the pilot trials have given direction for substances that ought to be further explored in more definitive studies. In men, randomized studies demonstrate that hot flashes are markedly decreased by low doses of megestrol acetate, moderately decreased by gabapentin, but not substantially decreased by clonidine. Results from the randomized trials in women demonstrate that hot flashes are markedly decreased by relatively low doses of progestational agents (megestrol acetate and medroxyprogesterone acetate), moderately decreased by venlafaxine, mildly to moderately decreased by fluoxetine, mildly decreased by clonidine, but not substantially decreased by vitamin E, a soy phytoestrogen product, or black cohosh. Last, the data investigated in these studies support the hypothesis that, for the treatment of hot flashes in women, the results of therapeutic maneuvers are similar regardless of whether the patient has a history of breast cancer and/or is taking tamoxifen.",
keywords = "Breast cancer, Hot flashes, Hot flushes",
author = "Loprinzi, {Charles Lawrence} and Barton, {Debra L.} and Sloan, {Jeff A} and Novotny, {Paul J.} and Dakhil, {Shaker R.} and Verdirame, {Joseph D.} and Knutson, {Wilma H.} and Joseph Kelaghan and Brad Christensen",
year = "2008",
month = "7",
doi = "10.1097/gme.0b013e3181679150",
language = "English (US)",
volume = "15",
pages = "655--660",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Mayo Clinic and North Central Cancer Treatment Group hot flash studies

T2 - A 20-year experience

AU - Loprinzi, Charles Lawrence

AU - Barton, Debra L.

AU - Sloan, Jeff A

AU - Novotny, Paul J.

AU - Dakhil, Shaker R.

AU - Verdirame, Joseph D.

AU - Knutson, Wilma H.

AU - Kelaghan, Joseph

AU - Christensen, Brad

PY - 2008/7

Y1 - 2008/7

N2 - Objective: This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group. Design: Prospective clinical trials performed by these investigators are illustrated, described, and discussed. Results: Ten randomized, controlled (eight placebo controlled), double-blind clinical trials were conducted involving a total of 1,581 women and three placebo-controlled, double-blind clinical trials involving a total of 329 men were conducted. In addition, 14 pilot trials, having involved more than 325 participants to date, were conducted. Conclusions: Data from the pilot trials have given direction for substances that ought to be further explored in more definitive studies. In men, randomized studies demonstrate that hot flashes are markedly decreased by low doses of megestrol acetate, moderately decreased by gabapentin, but not substantially decreased by clonidine. Results from the randomized trials in women demonstrate that hot flashes are markedly decreased by relatively low doses of progestational agents (megestrol acetate and medroxyprogesterone acetate), moderately decreased by venlafaxine, mildly to moderately decreased by fluoxetine, mildly decreased by clonidine, but not substantially decreased by vitamin E, a soy phytoestrogen product, or black cohosh. Last, the data investigated in these studies support the hypothesis that, for the treatment of hot flashes in women, the results of therapeutic maneuvers are similar regardless of whether the patient has a history of breast cancer and/or is taking tamoxifen.

AB - Objective: This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group. Design: Prospective clinical trials performed by these investigators are illustrated, described, and discussed. Results: Ten randomized, controlled (eight placebo controlled), double-blind clinical trials were conducted involving a total of 1,581 women and three placebo-controlled, double-blind clinical trials involving a total of 329 men were conducted. In addition, 14 pilot trials, having involved more than 325 participants to date, were conducted. Conclusions: Data from the pilot trials have given direction for substances that ought to be further explored in more definitive studies. In men, randomized studies demonstrate that hot flashes are markedly decreased by low doses of megestrol acetate, moderately decreased by gabapentin, but not substantially decreased by clonidine. Results from the randomized trials in women demonstrate that hot flashes are markedly decreased by relatively low doses of progestational agents (megestrol acetate and medroxyprogesterone acetate), moderately decreased by venlafaxine, mildly to moderately decreased by fluoxetine, mildly decreased by clonidine, but not substantially decreased by vitamin E, a soy phytoestrogen product, or black cohosh. Last, the data investigated in these studies support the hypothesis that, for the treatment of hot flashes in women, the results of therapeutic maneuvers are similar regardless of whether the patient has a history of breast cancer and/or is taking tamoxifen.

KW - Breast cancer

KW - Hot flashes

KW - Hot flushes

UR - http://www.scopus.com/inward/record.url?scp=51449099396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51449099396&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e3181679150

DO - 10.1097/gme.0b013e3181679150

M3 - Article

C2 - 18427355

AN - SCOPUS:51449099396

VL - 15

SP - 655

EP - 660

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 4

ER -